China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications
AD Pharmaceuticals successfully put its world-class biopharmaceutical base at China-Singapore Guangzhou Knowledge City into operation. The commissioning of the base has prepared AD Pharmaceuticals for the upcoming product commercialization, indicating that AD Pharmaceuticals has entered a new level of development.
AD Pharmaceuticals Co., Ltd. announced that patient enrollment has been completed ahead of schedule for the key registered Phase III clinical trial of the anti-PCSK9 monoclonal antibody Ebronucimab (R&D code: AK102), in the treatment of primary hypercholesterolemia and mixed hyperlipidemia.
Akeso, Inc. announced that it has received approval from the National Medical Products Administration (NMPA) to launch an open, multi-center Phase Ib/II clinical study on the treatment of patients with advanced solid tumors using self-developed Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104), a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently developed by Akeso, and VEGFR-2 monoclonal antibody (AK109) developed by AD Pharmaceuticals.